Galapagos NV Banner Image

Galapagos NV has reached its limit for free report views

Work for Galapagos NV? Upgrade Your Profile and unlock all your annual reports.

Galapagos NV

  • Ticker GLPG
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Galapagos NV Logo Image
  • 501-1000 Employees
  • Based in Mechelen, Belgium
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos’ pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Their target discovery platform has delivered three novel mechanismsMore showing promising patient results in, respectively, inflammatory diseases, idiopathic fibrosis and atopic dermatitis. Galapagos is focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 675 employees, operating from its Mechelen, Belgium headquarters and facilities in the Netherlands, France, Switzerland, the USA and Croatia.
Galapagos NV

Most Recent Annual Report

Galapagos NV MOST RECENT 2019 Annual Report

Report Locked. Galapagos NV has reached its limit for free report views.

Older/Archived Annual Reports